ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2021
BIOSOLVE-IV-registry: Safety and performance of the Magmaris scaffold: 12-month outcomes of the first cohort of 1,075 patients.
Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06409117 (3rd Generation Resorbable Magnesium Scaffolds vs Biodegradable Polymer Drug Eluting Stents in Patients With Non ST-segment Elevation Acute Coronary Syndromes), which is not on this map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
3rd Generation Resorbable Magnesium Scaffolds vs Biodegradable Polymer Drug Eluting Stents in Patients With Non ST-segment Elevation Acute Coronary Syndromes: the RESORB-ACS Randomized Clinical Trial
Who cites it
49 citing papers in PubMed, 72 citations in OpenAlex.
- Optimal Predilatation Treatment Before Implantation of a Magmaris Bioresorbable Scaffold in Coronary Artery Stenosis: The OPTIMIS Trial.Circulation. Cardiovascular interventions · 2025Trial
- A new resorbable magnesium scaffold for de novo coronary lesions (DREAMS 3): one-year results of the BIOMAG-I first-in-human study.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2023Trial
- First-in-human evaluation of a novel ultrathin sirolimus-eluting iron bioresorbable scaffold: 3-year outcomes of the IBS-FIM trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2023Trial
- Comparison of a Bioresorbable, Magnesium-Based Sirolimus-Eluting Stent with a Permanent, Everolimus-Eluting Metallic Stent for Treating Patients with Acute Coronary Syndrome: the PRAGUE-22 Study.Cardiovascular drugs and therapy · 2022Trial
- Cardiovascular stent technologies for coronary and valvular heart disease: the potential of 3D printing for stent fabrication.Nature reviews. Cardiology · 2026Review
- Advances in Functional Vascular Stents for Cardiovascular Therapy with Drug Delivery and Computational Design.Pharmaceutics · 2026Review
- A Comparison of Performance of the Different Generations of Magnesium-Based Bioresorbable Coronary Stents.Journal of clinical medicine · 2026Review
- Emerging Nanomaterials Can Even Treat Chronic Wounds: A Review of Evidence on Magnesium-Based Systems.International journal of nanomedicine · 2026Review
- Development and translation of biodegradable metal stents: from heart to brain.Regenerative biomaterials · 2026Review
- Bioresorbable Scaffolds for Coronary Revascularization: From Concept to Clinical Maturity.Journal of cardiovascular development and disease · 2025Review
- Magnesium-based bioresorbable flow diverter for intracranial aneurysms: a pilot study of biocompatibility and bioresorption in a rabbit vascular model.Journal of neurointerventional surgery · 2025Article
- Article
- Preclinical research models for evaluating the biocompatibility of bioresorbable metallic cardiovascular stents: A comparative review.Bioactive materials · 2025Review
- Late Thrombosis of First-Generation Bioresorbable Scaffold Site Treated With Novel Resorbable Magnesium Scaffold.JACC. Case reports · 2025Article
- Biodegradable Metal-Based Stents: Advances, Challenges, and Prospects.Journal of functional biomaterials · 2025Review
- Evaluation of FeMnN alloy bioresorbable flow diverting stents in the rabbit abdominal aorta.Bioactive materials · 2025Article
- The Impact of Underlying Plaque Characteristics Following the Third-Generation Resorbable Magnesium Scaffold Implantation: An Intravascular OCT Assessment up to 12-Months.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2025Article
- The Safety and Efficacy Profile of Magnesium-Based Bioresorbable Coronary Stents as Compared to Poly-L-Lactic Acid-Based Bioresorbable and Contemporary Drug-Eluting Coronary Stents-A Systematic Review.Cardiology research and practice · 2025Review
- Semi-quantitative elemental imaging of corrosion products from bioabsorbable Mg vascular implantsBioactive materials · 2025Article
- Protection mechanism investigation of a protective coating on magnesium alloy stents via deformation model construction and the simulation of cellular automata.Regenerative biomaterials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 12 institutions in 8 countries.
Funding
Abstract
objectivesWe aimed to assess the safety and performance of the Magmaris sirolimus-eluting bioresorbable magnesium scaffold in a large patient population.
backgroundMagmaris has shown good outcomes in small-sized controlled trials, but further data are needed to confirm its usability, safety, and performance.
methodsBIOSOLVE-IV is an international, single arm, multicenter registry including patients with a maximum of two single de novo lesions. Follow-up is scheduled up to 5 years; the primary outcome is target lesion failure (TLF) at 12 months.
resultsA total of 1,075 patients with 1,121 lesions were enrolled. Mean patient age was 61.3 ± 10.5 years and 19.2% (n = 206) presented with non-ST-elevation myocardial infarction (NSTEMI). Lesions were 3.2 ± 0.3 mm in diameter and 14.9 ± 4.2 mm long; 5.1% (n = 57) were bifurcation lesions. Device success was 97.3% (n = 1,129) and procedure success 98.9% (n = 1,063). The Kaplan-Meier estimate of TLF at 12 months was 4.3% [95% confidence interval, CI: 3.2, 5.7] consisting of 3.9% target lesion revascularizations, 0.2% cardiac death, and 1.1% target-vessel myocardial infarction. Definite/probable scaffold thrombosis occurred in five patients (0.5% [95% CI: 0.2, 1.1]), thereof four after early discontinuation of antiplatelet/anticoagulation therapy.
conclusionBIOSOLVE-IV confirms the safety and performance of the Magmaris scaffold in a large population with excellent device and procedure success and a very good safety profile up to 12 months in a low-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.